Racial differences in paraoxonase-1 (PON1): A factor in the health of southerners?

Environmental Health Perspectives

Volumn 117, Issue 8, 2009, Pages 1226-1231

  Davis, Kimberly A ^a   Crow, J Allen ^a   Chambers, Howard W ^b   Meek, Edward C ^a   Chambers, Janice E ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

Atherosclerosis; C reactive protein; Cardiovascular disease; Health disparities

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; C REACTIVE PROTEIN; COTININE; HIGH DENSITY LIPOPROTEIN; LIPID; ORGANOPHOSPHATE INSECTICIDE;

ADULT; AFRICAN AMERICAN; ARTICLE; ATHEROSCLEROSIS; BLOOD BANK; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CAUCASIAN; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEALTH STATUS; HUMAN; LIPID HYDROLYSIS; LIPID OXIDATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; RISK REDUCTION; SEX DIFFERENCE; SPECTROPHOTOMETRY; UNITED STATES;

ADULT; AFRICAN AMERICANS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; SOUTHEASTERN UNITED STATES;

EID: 69249139141     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.0900569     Document Type: Article

References (39)

1. American Heart Association. 2005. Heart Disease and Stroke Statistics - 2005 Update. Dallas, TX:American Heart Association.
2. Ayub A, Mackness M, Arrol S, Mackness B, Patel J, Durrington PN. 1999. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 19:330-335.
3. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. 2008. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299:1265-1276.
4. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. 2008. C-reactive protein and coronary heart disease: a critical review. J Intern Med 264:295-314.
5. Chambers H, Brown B, Chambers JE. 1990. Noncatalytic detoxication of six organophosphorus compounds by rat liver homogentes. Pestic Biochem Physiol 36:308-315.
6. Chambers J. 2008. PON1 multitasks to protect health. Proc Natl Acad Sci USA 105:12639-12640.
7. Chen J, Chan W, Wallenstein S, Berkowitz G, Wetmur J. 2005. Haplotype-phenotype relationships of paraoxonase-1. Cancer Epidemiol Biomarkers Prev 14(3):731-734.
8. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JW. 2003. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect 111:1403-1409.
9. Costa LG, Vitalone A, Cole JB, Furlong CE. 2005. Modulation of paraoxonase 1 (PON1) activity. Biochem Pharmacol 69:541-550.
10. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. 1999. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100:717-722.
11. Deakin S, Leviev I, Gomaraschi M, Calabrisi L, Franceschini G, Shih DM, et al. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 277:4301-4308.
12. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. 2005. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46:1239-1247.
13. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. 2006. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res 47:2492-2502.
14. Gardemann A, Philipp M, Hess K, Katz N, Tillmanns H, Haberbosch W. 2000. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 152:421-431.
15. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. 2004. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 5:412-419.
16. James RW, Deakin SP. 2004. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 37:1986-1994.
17. James RW, Leviev I, Righetti A. 2000. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252-2257.
18. 55 genotype. Arterioscler Thromb Vasc Biol 20:2441-2447.
19. Jarvik GP, Tsai TN, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. 2002. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 22:1329-1333.
20. Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, Matthews KA, Johnston J, Sowers MR, et al. 2008. Ethnic differences in C-reactive protein concentrations. Clin Chem 54:1027-1037.
21. Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB, et al. 2006. Gender and C-reactive protein: data from the multiethnic study of atherosclerosis. Am Heart J 152:593-598.
22. Mackness B, Gershan KD, Turkie W, Lee E, Roberts DH, Hill E, et al. 2001. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21:1451-1457.
23. Milochevitch C, Khalil A. 2001. Study of the paraoxonase and platelet- activating factor acetylhydrolase activities with aging. Prostagl Leukot Essent Fatty Acids 65:241-246.
24. Mueller RF, Hornung S, Furlong CE, Anderson J, Giblett ER, Motulsky AG. 1983. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am J Hum Genet 35:393-408.
25. Nishio E, Watanabe Y. 1997. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 236:289-293.
26. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al. 1998. The Gln-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 18:1611-1616.
27. Ozer EA, Pezzulo A, Shih DM, Chun C, Furlong C, Lusis AJ, et al. 2005. Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol Lett 253:29-37.
28. Perry HM, Roccella EJ. 1998. Conference report on stroke mortality in the southeastern United States. Hypertension 31:1206-1215.
29. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice, a statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511.
30. Richter RJ, Furlong CE. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9:745-753.
31. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. 1999. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100:713-716.
32. Scacchi R, Corbo RM, Rickards O, Stefano GF. 2003. New data on the world distribution of paraoxonase (PON1 Gln192-Arg) gene frequencies. Hum Biol 75:365-373.
33. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287.
34. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. 1999. Human serum paraoxonase/arylesterases retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 19:2214-2225.
35. Stoltz DA, Ozer EA, Taft PJ, Barry M, Liu L, Kiss PJ, et al. 2008. Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1. J Clin Invest 118:3123-3131.
36. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, et al. 2002. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106:484-490.
37. Van Himbergen TM, van Tits LJH, Roest M, Stalenhoef AFH. 2006. The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 64:34-38.
38. Wall MA, Johnson J, Jacob P, Benowitz NL. 1988. Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers. Am J Public Health 78(6):699-701.
39. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. 2004. Four paraoxonase gene polymorphisms 11,212 of coronary heart disease and 12,786 controls: meta-analysis of 43 studies. Lancet 363:689-695.